Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamBeutner KR, Geisse JK, Helman D, Fox TL, Ginkel A, Owens MLJ Am Acad Dematol. 1999;41:1002-1007
The incidence of basal cell carcinomas (BCCs) is very high. Despite the effectiveness of surgical treatments, the development of effective biologic therapies for BCC is important.1 Beutner et al2 performed a randomized, double-blind pilot trial evaluating the safety and efficacy of imiquimod 5% cream vs vehicle in the treatment of BCCs.
Jan N. Bouwes Bavinck. Biologic Treatment of Basal Cell Carcinoma. Arch Dermatol. 2000;136(6):774–775. doi:10.1001/archderm.136.6.774